Perfood

Perfood develops digital therapeutics that use continuous glucose monitoring and AI to create personalized low glycemic nutrition plans, addressing metabolic and neuro-inflammatory conditions.

- Commercialized 2 products (Migraine & Type 2 Diabetes) in Germany under the DiGA pathway, making them 100% reimbursable by public health insurance
- Served over 20,000 patients in Germany
- Proofed the products clinical effectiveness through 9 published peer reviewed clinical studies
- Filed one global patent
- Established commercial partnerships with the worlds leading CGM manufacturers, Dexcom and Abbott
- Started global expansion (France and USA) in 2024 to expand impact and attract potential long term strategic partner and acquirers

Over 80% of global diseases are nutrition-related, affecting 3.4 billion people. Poor metabolic health causes 74% of global deaths and incurs $3.7 trillion in US medical expenses. Glucose metabolism is a key factor in many conditions, currently treated with drugs that often only manage symptoms and are costly to develop, ranging from $800M to $2.7B. Thus, drugs for diseases like migraine or type 2 diabetes are expensive and ineffective in solving the root problem. A lot of the other dietary solutions are only general diets without personalization and require drastic life changes.

Our drug-free digital therapies are as effective as medications, helping patients address the root cause without side effects. Central to Perfoods therapeutic approach is the emphasis on a low glycemic diet as an active ingredient. Utilizing continuous glucose monitoring (CGM) data and advanced AI algorithms, our products automatically generate personalized nutrition plans and predict individual glucose responses, empowering patients to stabilize their blood sugar levels effectively. Thereby we identify the slightest life style change needed to have the biggest health impact.

- In Germany and France our business model is based on the DiGA / PECAN reimbursement pathway, which allow digital therapeutics to be prescribed and reimbursed like medications after having gone through rigorous clinical trials. Our products are marketed directly to physicians and patients to increase awareness and prescription numbers.
- In the US, we are currently building partnerships to conduct clinical trials to proof the effectiveness of the therapies in the US. After this we will target health plans and employers, preferably in commercial partnerships with Pharma / MedDevice companies.

H7 Bio Capital
German Accelerator